Medicare Coverage for GLP-1 Weight Loss Drugs: 2026 Update

Over 60 million Americans rely on Medicare for their healthcare coverage, and a significant percentage of them live with obesity. Yet Medicare has historically excluded coverage for weight loss medications — a policy rooted in a 2003 law that explicitly prohibited Medicare Part D from covering drugs used for "anorexia, weight loss, or weight gain." As GLP-1 medications have demonstrated profound benefits beyond weight loss, including cardiovascular protection and diabetes management, pressure to change this policy has intensified. Here is where things stand in 2026.

The Current Coverage Landscape

What Medicare Part D Covers

Medicare Part D (prescription drug coverage) currently covers GLP-1 medications when prescribed for FDA-approved indications other than weight loss:

• Ozempic (semaglutide): Covered for type 2 diabetes
• Mounjaro (tirzepatide): Covered for type 2 diabetes
• Rybelsus (oral semaglutide): Covered for type 2 diabetes
• Trulicity (dulaglutide): Covered for type 2 diabetes

What Medicare Part D Does NOT Cover

• Wegovy (semaglutide 2.4 mg): Not covered — approved solely for weight management
• Zepbound (tirzepatide): Not covered — approved solely for weight management
• Saxenda (liraglutide 3 mg): Not covered — approved solely for weight management
• Contrave, Qsymia, orlistat: Not covered — classified as weight loss medications

Why Medicare Excludes Weight Loss Drugs

The exclusion traces back to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which created Medicare Part D. Section 1860D-2(e)(2)(A) of the Social Security Act specifically lists drugs "used for anorexia, weight loss, or weight gain" among the excluded categories. This language predates the recognition of obesity as a chronic disease and the development of GLP-1 medications with broad metabolic benefits.

The original exclusion was partly cost-driven — Congress was concerned about the budget impact of covering weight loss treatments for millions of beneficiaries. At the time, available weight loss medications had modest efficacy and limited medical evidence. The landscape has changed dramatically since then.

The Cardiovascular Coverage Pathway

A significant development occurred when semaglutide received an FDA-approved indication for cardiovascular risk reduction following the SELECT trial results. This created a potential pathway for Medicare coverage independent of the weight loss exclusion:

• Wegovy received an indication for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
• Some Medicare Part D plans began evaluating whether to cover Wegovy under this cardiovascular indication, which falls outside the "weight loss" exclusion
• CMS (Centers for Medicare and Medicaid Services) has been reviewing whether the cardiovascular indication qualifies Wegovy for Part D coverage

This remains an evolving area. As of April 2026, coverage through the cardiovascular pathway is not universally available across Medicare Part D plans, but some plans have begun offering it. Check with your specific plan.

Legislative Efforts: The TREAT Act and Beyond

The most significant legislative effort to change Medicare's weight loss drug exclusion is the TREAT Act (Treat and Reduce Obesity Act). This bipartisan bill would:

• Remove the statutory exclusion of anti-obesity medications from Medicare Part D
• Allow Medicare to cover FDA-approved weight loss medications
• Expand Medicare coverage for obesity screening and counseling services

The TREAT Act has been introduced in multiple Congressional sessions and has gained increasing support from medical organizations, patient advocacy groups, and bipartisan lawmakers. However, concerns about the cost impact on Medicare (estimated at tens of billions of dollars annually) have slowed its passage.

The Cost Question: What Would Coverage Mean for Medicare?

The Congressional Budget Office (CBO) and other analysts have estimated that covering anti-obesity medications under Medicare could cost $35-50 billion or more over 10 years, depending on utilization rates and drug pricing. This significant cost has been the primary obstacle to legislative change.

Proponents argue that the cost of covering weight loss medications would be offset by reduced spending on obesity-related conditions:

• Type 2 diabetes care costs Medicare approximately $42 billion annually
• Cardiovascular disease related to obesity costs Medicare billions more
• Obesity-related hospitalizations, joint replacements, and other procedures add further costs
• Weight loss of 10-20% has been shown to reduce medication needs, hospitalizations, and surgical interventions

Whether the savings would fully offset medication costs is debated among health economists, but there is growing consensus that some offset would occur.

Medicare Advantage: A Partial Solution?

Medicare Advantage (Part C) plans, offered by private insurers, have more flexibility than traditional Medicare in what supplemental benefits they offer. Some Medicare Advantage plans have begun including:

• Weight management programs as supplemental benefits
• Nutrition counseling and meal delivery services
• Fitness program subsidies (SilverSneakers, etc.)
• Limited coverage for specific weight loss interventions

However, coverage of GLP-1 medications specifically for weight loss through Medicare Advantage remains rare. The plans are still bound by the broader Medicare coverage rules for prescription drugs, though some have found creative ways to offer partial benefits.

What Medicare Beneficiaries Can Do Now

If you are a Medicare beneficiary seeking GLP-1 medications for weight loss, here are your current options:

1. Check for Diabetes Coverage

If you have a type 2 diabetes diagnosis, GLP-1 medications like Ozempic and Mounjaro are covered under Medicare Part D for diabetes management. Weight loss is a beneficial side effect in this context.

2. Explore the Cardiovascular Indication

If you have established cardiovascular disease and obesity, ask your provider about Wegovy's cardiovascular risk reduction indication. Some Medicare Part D plans may cover it for this purpose.

3. Consider Compounded Options

Compounded semaglutide and tirzepatide through Trimi offer significantly lower out-of-pocket costs for patients paying cash. This bypasses insurance entirely and makes treatment accessible at a fraction of brand-name prices.

4. Look Into Patient Assistance Programs

Pharmaceutical manufacturers offer patient assistance programs for qualifying low-income patients. Novo Nordisk and Eli Lilly both have programs that may help Medicare beneficiaries access medications at reduced cost.

5. Use HSA Funds (If Applicable)

Some Medicare beneficiaries may have existing HSA funds from prior years that can be used for weight loss medications. Note that you cannot contribute new funds to an HSA while enrolled in Medicare, but existing balances can be spent. Learn more about using HSA/FSA for weight loss.

Looking Ahead

The trajectory is clear: the medical evidence supporting GLP-1 medications continues to strengthen, public support for coverage is growing, and legislative efforts are gaining momentum. Whether through the TREAT Act, CMS administrative action, or the cardiovascular coverage pathway, Medicare coverage for weight loss medications appears increasingly likely — the question is when, not if.

In the meantime, Medicare beneficiaries should not delay treatment if they need it. Affordable options exist, and the health benefits of treating obesity are well-established. Talk to a Trimi provider about accessible treatment options while the coverage landscape evolves.

Frequently Asked Questions